Inflammation is increasingly recognised as a causal factor in the development and progression of cardiovascular disease. With the introduction of immune checkpoint inhibitors in oncology and the ongoing COVID-19 pandemic the role of the immune system in myocardial inflammation (myocarditis) and subsequent inflammatory cardiomyopathy has once again regained attention. In this review, we want to bring myocardial inflammation to the clinician's attention and provide up-to-date knowledge on its diagnostic workup, prognostication, and current management recommendations.
|Bidragets oversatte titel||Myocarditis and development of dilated cardiomyopathy|
|Tidsskrift||Ugeskrift for Læger|
|Status||Udgivet - 13 jun. 2022|
- Cardiomyopathy, Dilated/diagnosis